Market starts off 2023 with a bang, rebounds for winning week. Plus, a new Alzheimer’s drug approval. 1/6/23
Update: 2023-01-06
Description
Stocks rally Friday after a seemingly ‘goldilocks’ jobs report, with consumer-leveraged stocks among the biggest winners. Plus, an exclusive with the EISAI US CEO - which worked with Biogen on the FDA’s approval of its Alzheimer’s treatment that slowed cognitive decline in a clinical trial.
Comments